Elsevier

Vaccine

Volume 29, Issue 23, 23 May 2011, Pages 4013-4018
Vaccine

Ethnic and racial differences in HPV knowledge and vaccine intentions among men receiving HPV test results

https://doi.org/10.1016/j.vaccine.2011.03.060Get rights and content

Abstract

We examined factors associated with HPV vaccine intentions by racial/ethnic group among men participating in a HPV natural history study. HPV knowledge, vaccine intentions and perceived barriers were assessed among non-Hispanic White, non-Hispanic Black and Hispanic men. Men were tested for HPV every 6 months. After receiving test results from their previous visit, participants (N = 477) reported their intentions for HPV vaccination in a computer-assisted survey instrument (CASI). Vaccine intentions were high among all respondents, although differences were found between racial and ethnic groups in awareness and knowledge of HPV and, vaccine intentions and perceived access and barriers to receiving the HPV vaccine. In order to effectively disseminate the vaccine among men, factors that may promote or inhibit vaccine acceptability need to be identified. Identifying these factors related to vaccine intentions among minority and majority men offers an opportunity for addressing barriers to health equity and, in turn, reductions in HPV-related disparities.

Introduction

Human papillomavirus (HPV), the most common sexually transmitted virus in the United States (U.S.), remains a considerable public health problem [1]. Although most attention has been directed to cervical cancer, the most common HPV-related cancer, HPV has been indicated in 40% of vulvar and vaginal cancers, 40% of penile cancers, 90% of anal cancers [2], [3], [4] and 25–63% of head and neck cancers in the U.S. [2], [3], [4], [5], [6], [7]. Racial/ethnic minorities account for a disproportionate number of HPV-related cancers [8]. Greater proportions of Black and Hispanic men and women are diagnosed with HPV-related cancers and are diagnosed at later stages of the disease than men and women of other races or ethnicities [9], [10], [11], [12], [13], [14]. Thus, race and ethnicity, or associated factors, play a fundamental role in the epidemiology of HPV-related cancer in the U.S.

In 2006, the Food and Drug Administration (FDA) approved a prophylactic quadrivalent HPV vaccine for women (9–26 years) [15] and recently in 2009, the FDA approved the quadrivalent HPV vaccine for use in preventing HPV 6 and 11 related to genital warts in males ages 9–26 years [16]. Numerous studies evaluating the acceptability of and the attitudes towards the HPV vaccine have been conducted, but few have examined acceptability among racial and ethnic minority men [17]. Across racial/ethnic groups, factors associated with vaccine acceptance among men include knowledge of HPV, perceived threat, and perceived barriers to HPV vaccine [17], [18], [19], [20]. Previous research conducted with men found low levels of awareness and knowledge about HPV [21], [22], [23]. Acceptability of the HPV vaccine was on average higher in studies conducted with gay and bi-sexual men (47–74%) than studies conducted with heterosexual men (37–78%) [17], [21], [22], [23], [24]. These rates also varied based on how the vaccine was framed, and there was a general preference for a vaccine that protected against more types of HPV and that provided some direct protection for males [24], [25]. Vaccine acceptance is generally higher among men who perceive themselves to be at risk for HPV infection, those with higher lifetime partners and those with greater anticipated regret if they did not get vaccinated and later had an HPV infection [21], [22], [25], [26]. Perceived barriers to vaccination often include concerns about vaccine safety, side effects, costs, and fear of shots [18], [19], [23], [26]. Additionally, it is well documented that a physician's recommendation plays a significant role in the decision to be vaccinated [21], [27], [28], [29], [30], [31], and physicians who currently vaccinate women support vaccinating men [31]. Understanding factors related to vaccine intentions among racial and ethnic minority populations is critical, because disparities in other types of immunization and vaccinations remain an important public health concern, and addressing potential disparities now may be key to preventing major disparities [32].

The purpose of this current investigation is to examine whether there are racial and ethnic differences among men in: (a) factors associated with vaccine uptake, including knowledge of HPV and other demographic factors; (b) barriers to HPV vaccination; (c) importance of provider recommendation; and (d) vaccine intentions. Results from this study will inform future HPV vaccine interventions among racial and ethnic minority men at high risk for HPV-related cancers.

Section snippets

Study design and population

The Cognitive and Emotional Responses to HPV in Men (CER) Study is the behavioral arm of a Natural History Study of HPV Infection in Men (the HIM study) [33]. The CER survey was developed as a computer-assisted survey instrument (CASI) that measures theoretically-based constructs related to cognitive and emotional responses to an HPV test result. The constructs in the survey were derived from the Parallel Processing Model and Common Sense Model (Leventhal), the Extended Parallel Processing

Sample characteristics

Of 477 respondents, 307 (64%) identified as non-Hispanic White, 78 (16%) as non-Hispanic Black, and 90 (19%) as Hispanic. Self-reported HPV status did not differ among these 3 groups. The mean age of participants was 31 years (range 18–69). Overall, men in this sample had high scores on the HPV knowledge scale (mean = 15, SD = 3) and reported having at least some college education (87%). Compared to non-Hispanic White men, a greater proportion of non-Hispanic Black men reported ever having had

Discussion

One of the four goals outlined in Healthy People 2020 is “achieve health equity, eliminate disparities, and improve the health of all groups [36].” Strategies of this initiative to avert vaccine-preventable diseases include: improved quality and quantity of vaccination services; minimization of financial burden for disadvantaged persons; increased community participation, education, and leadership; improved disease monitoring and vaccine coverage; and development of new or improved vaccines.

Acknowledgement

This study is funded by the National Institutes of Health, National Cancer Institute (Grant# 1R01 CA123346).

References (46)

  • H. De Vuyst et al.

    Prevalence and type distribution of human papillomavirus in carcinoma and intraepithelial neoplasia of the vulva, vagina and anus: a meta-analysis

    Int J Cancer

    (2009)
  • M.L. Gillison et al.

    HPV prophylactic vaccines and the potential prevention of noncervical cancers in both men and women

    Cancer

    (2008)
  • Assessing the Burden of HPV-Associated Cancers in the United States (ABHACUS). Cancer...
  • M. Watson et al.

    Burden of cervical cancer in the United States, 1998-2003

    Cancer

    (2008)
  • N.R. Patel et al.

    Racial and ethnic disparities in the incidence of invasive cervical cancer in Florida

    Cancer

    (2009)
  • J. Barnholtz-Sloan et al.

    Incidence trends of invasive cervical cancer in the United States by combined race and ethnicity

    Cancer Causes Control

    (2009)
  • L.A.G. Ries et al.

    SEER cancer statistics review

    1975-2002. Bethesda, MD: National Cancer Institute;

    (2002)
  • A.B. Ryerson et al.

    Burden of potentially human papillomavirus-associated cancers of the oropharynx and oral cavity in the US, 1998-2003

    Cancer

    (2008)
  • B.Y. Hernandez et al.

    Burden of invasive squamous cell carcinoma of the penis in the United States, 1998-2003

    Cancer

    (2008)
  • S.M. Garland et al.

    Quadrivalent vaccine against human papillomavirus to prevent anogenital diseases

    N Engl J Med

    (2007)
  • Centers for Disease Control and Prevention

    FDA Licensure of quadrivalent human papillomavirus vaccine (HPV4, Gardasil) for use in males and guidance from the Advisory Committee on Immunization Practices (ACIP)

    MMWR

    (2010)
  • D.G. Ferris et al.

    Variables associated with human papillomavirus (HPV) vaccine acceptance by men

    J Am Board Fam Med

    (2009)
  • M.A. Gerend et al.

    Human papillomavirus vaccine acceptability among young adult men

    Sex Transm Dis

    (2008)
  • Cited by (31)

    • On-time, late, or never: Incorporating intersectionality to predict age-specific probabilities of initiating the HPV vaccine series

      2021, Social Science and Medicine
      Citation Excerpt :

      In 2011 it became available to all, yet remained marketed as a cervical cancer preventative. This marketing socially constructs HPV as a girl/woman-only health issue (Daley et al. 2011), as well as a heterosexual issue, while failing to account for how boys/men, nonbinary individuals, and queer populations are at risk of developing HPV and HPV-related illnesses. Adolescent girls are significantly more likely to receive provider HPV vaccine recommendation than boys (Mohammed et al., 2016), which reflect providers’ attitudes in prioritizing girls.

    • Human papillomavirus infection and related diseases among men

      2019, Human Papillomavirus: Proving and Using a Viral Cause for Cancer
    • HPV vaccine awareness and the association of trust in cancer information from physicians among males

      2017, Vaccine
      Citation Excerpt :

      However, males receive fewer recommendations for the HPV vaccine from health care providers and men who are ethnic and racial minorities do not trust information from physicians [19,20]. Although ethnic and racial minority men experience HPV-related disparities, few studies have concurrently examined HPV knowledge, the HPV vaccine and the trust in information from health care providers among this population [5,10,21,22]. Therefore the purpose of this study is to: (1) assess awareness of men about HPV and HPV vaccine by race/ethnicity and (2) examine the association of trust in information from physicians about cancer and ever hearing about HPV and the HPV vaccine.

    • HPV vaccination among adolescent males: Results from the National Immunization Survey-Teen

      2013, Vaccine
      Citation Excerpt :

      Initial estimates found that only about 2% of adolescent males had received any HPV vaccine doses by the end of 2010 [12–14], with a slight increase to about 8% by the end of 2011 [15,16]. Although several studies have examined correlates of HPV vaccine uptake among adolescent females [17] and vaccine acceptability for males [14,18–25], only a few studies have identified correlates of HPV vaccine uptake among adolescent males and reasons why parents are not vaccinating their sons [13,16,26,27]. We analyzed provider-verified vaccination data from a nationally representative sample of adolescent males to provide insight into HPV vaccine uptake among males.

    View all citing articles on Scopus
    View full text